Developments in pharmacological therapy for the overactive bladder

BJU International

Volumn 98, Issue SUPPL. 1, 2006, Pages 78-87

  Chapple, Christopher R ^a,c   Gormley, E Ann ^b  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Adrenoceptor; Agonist; Antagonist; Anticholinergics; Botulinum toxin; Cholinergic muscarinic receptors; Detrusor overactivity; Overactive bladder; Pharmacotherapy; Vanilloids

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; BACLOFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CALCIUM ANTAGONIST; CAPSAICIN; CHOLINERGIC RECEPTOR; DARIFENACIN; DICYCLOVERINE; DOXAZOSIN; FLAVOXATE; HYOSCYAMINE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; POTASSIUM CHANNEL STIMULATING AGENT; PRAZOSIN; PROPANTHELINE BROMIDE; PROPIVERINE; PROSTAGLANDIN INHIBITOR; RESINIFERATOXIN; SOLIFENACIN; TAMSULOSIN; TERAZOSIN; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG; VASOPRESSIN DERIVATIVE;

CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DETRUSOR DYSSYNERGIA; DETRUSOR MUSCLE; DOSE CALCULATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TARGETING; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MICTURITION; MUSCLE HYPOTONIA; NEUROTRANSMISSION; NONHUMAN; OBESITY; OVERACTIVE BLADDER; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; XEROSTOMIA;

DRUG DESIGN; FEMALE; HUMANS; URINARY INCONTINENCE; URODYNAMICS;

EID: 33746728340     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06381.x     Document Type: Review

References (97)

1. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the Standardization Subcommittee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78
2. Stewart W, Herzoz R, Wein A, Abrams P. The prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodyn 2001; 20: 406-8
3. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004; 63: 461-5
4. Burgio KL, Locher JL, Goode PS. Combined behavioural and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000; 48: 370-4
5. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36
6. Coyne KS, Payne C, Bhattacharyya SK et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004; 7: 455-63
7. Chapple CR, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005; 95: 335-40. Erratum in: BJU Int 2005; 95: 924
8. Kobelt G, Kirchberger I, Malone-Lee J. Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999; 83: 583-90
9. O'Conor RM, Johannesson M, Hass SL, Kobelt-Nguyen G. Urge incontinence. Quality of life and patients' valuation of symptom reduction. Pharmacoeconomics 1998; 14: 531-9
10. Brown JS, McNaughton KS, Wyman JF et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology, 2003; 61: 802-9
11. Cardozo L, Dixon A. Increased warning time with darifenacin; a new concept in the management of urinary urgency. J Urol 2005; 173: 1214-8
12. Zinner N, Susset J, Gittleman M, Arguinzoniz M, Rekeda L, Haab F. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract 2006; 60: 119-26
13. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-90
14. Chess-Williams R, Chapple CR, Yamanishi T, Yasuda K, Sellers DJ. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 2001; 21: 243-8
15. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 1995; 273: 959-66
16. Schneider T, Fetscher C, Krege S, Michel MC. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 2004; 309: 1148-53
17. Nakamura T, Kimura J, Yamaguchi O. Muscarinic M2 receptors inhibit Ca2+- activated K+ channels in rat bladder smooth muscle. Int J Urol 2002; 9: 689-96
18. An JY, Yun HS, Lee YP et al. The intracellular pathway of the acetylcholine-induced contraction in cat detrusor muscle cells. Br J Pharmacol 2002; 137: 1001-10
19. Wibberley A, Chen Z, Hu E, Hieble JP, Westfall TD. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br J Pharmacol 2003; 138: 757-66
20. Fleichman M, Schneider T, Fetscher C, Michel MC. Signal transduction underlying carbachol-induced contraction of rat urinary bladder. II. Protein kinases. J Pharmacol Exp Ther 2004; 308: 54-8
21. Matsui M, Motomura D, Karasawa H et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Nat Acad Sci USA 2000; 97: 9579-84
22. Stengel PW, Gomeza J, Wess J, Cohen ML. M(2) and M(4) receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J Phamacol Exp Ther 2000; 292: 877-85
23. Matsui M, Motomura D, Fujikawa T et al. Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J Neurosci 2002; 22: 10627-32
24. Igawa Y, Zhang X, Nishizawa O et al. Cystometric findings in mice lacking muscarinic M2 or M2 receptors. J Urol 2004; 172: 2460-4
25. Braverman AS, Luthin GR, Ruggieri MR. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol 1998; 275: R1654-60
26. Pontari MA, Braverman AS, Ruggieri MR Sr. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol 2004; 286: R874-80
27. Stevens LA, Sellers DJ, Chapple CR, Chess-Williams R. A comparison of muscarinic receptor function in the normal and neurogenic overactive bladder. J Urol 2004; 171 (Suppl. 4): 143, 535
28. Stevens LA, Sellers DJ, Chapple CR, Chess-Williams R. Muscarinic receptor function in the idiopathic overactive bladder. J Urol 2004; 171 (Suppl. 4): 140, 527
29. Andersson KE, Appell R, Cardozo L et al. Pharmacological treatment of urinary incontinence. In Abrams P, Cardozo L, Khoury S, Wein A eds, Incontinence, 3rd International Consultation on Incontinence, Vol. 2, Chapter 14. Paris: Health Publication Ltd, 2005: 809-855
30. Tolterodine (Detrol) package insert. Kalamazoo, MI: Pharmacia Corporation, 2003
31. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55 (Suppl. 5A): 33-46
32. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001; 41: 636-44
33. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173: 493-8
34. Haab F, Stewart K, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45: 420-9
35. Noronha-Blob L, Kachur JF. Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther 1991; 256: 562-7
36. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326: 841-4
37. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48: 5-26
38. Appell RA, Sand P, Dmochowski R et al.; Overactive Bladder. Judging Effective Control and Treatment Study Group. Prospective randomised controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001; 76: 358-63
39. Diokno AC, Appell RA, Sand PK et al. Prospective, randomised, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78: 687-95
40. Sand PK, Miklos J, Ritter H, Appell R. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct 2004; 15: 243-8
41. Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol 2004; 22: 251-6
42. Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics 2004; 22: 1047-59
43. Chapple CR, Rechberger T, Al-Shukri S et al.; YM-905 Study Group. Randomised, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10
44. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A; Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 414-21
45. Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo-controlled trial of once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919-24
46. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004; 93: 71-7
47. Drake MJ, Headlund P, Harvey IJ, Pandita RK, Andersson KE, Gillespie JI. Partial outlet obstruction enhances modular autonomous activity in the isolated rat bladder. J Urol 2003; 170: 276-9
48. Gillespie JI, Markerink-van Ittersum M, de Vente J. cGMP-generating cells in the bladder wall: identification of distinct networks of interstitial cells. BJU Int 2004; 94: 1114-24
49. Gillespie JI. Modulation of autonomous contractile activity in the isolated whole bladder of the guinea pig. BJU Int 2004; 93: 393-400
50. Gillespie JI. The autonomous bladder: a review of the origin of bladder overactivity and sensory urge. BJU Int 2004; 93: 478-83
51. Gillespie JI. Noradrenaline inhibits autonomous activity in the isolated guinea-pig bladder. BJU Int 2004; 93: 401-9
52. Gillespie J. Inhibitory actions of calcitonin gene-related peptide and capsaicin: evidence for local axonal reflexes in the bladder wall. BJU Int 2005; 95: 149-56
53. Gillespie JI, Drake MJ. The actions of sodium nitroprusside and the phosphodiesterase inhibitor dipyridamole on phasic activity in the isolated guinea-pig bladder. BJU Int 2004; 93: 851-8
54. Gillespie JI. Phosphodiesterase-linked inhibition of nonmicturition activity in the isolated bladder. BJU Int 2004; 93: 1325-32
55. Lagou M, Drake MJ, Gillespie JI. Volume-induced effects on the isolated bladder: a possible local reflex. BJU Int 2004; 94: 1356-65
56. Fry CH, Sui GP, Severs NJ, Wu C. Spontaneous activity and electrical coupling in human detrusor smooth muscle: implications for detrusor overactivity? Urology 2004; 63 (Suppl. 3): 3-10
57. Montgomery BS, Fry CH. The action potential and net membrane currents in isolated human detrusor smooth muscle cells. J Urol 1992; 147: 176-84
58. Hashitani H, Brading AF, Suzuki H. Correlation between spontaneous electrical, calcium and mechanical activity in detrusor smooth muscle of the guinea-pig bladder. Br J Pharmacol 2004; 141: 183-93
59. Sanders K. A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology 1996; 111: 492-515
60. Hirst GD, Ward SM. Interstitial cells: involvement in rhythmicity and neural control of gut smooth muscle. J Physiol 2003; 550: 337-46
61. Sui GP, Rothery S, Dupont E, Fry CH, Severs NJ. Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int 2002; 90: 118-29
62. Sui GP, Wu C, Fry CH. Electrical characteristics of suburothelial cells isolated from the human bladder. J Urol 2004; 171: 938-43
63. Kumar V, Chapple CR, Chess-Williams R. Characteristics of adenosine triphosphatase release from porcine and human normal bladder. J Urol 2004; 172: 744-7
64. McCloskey KD, Gurney AM. Kit positive cells in the guinea pig bladder. J Urol 2002; 168: 832-6
65. Hashitani H, Yanai Y, Suzuki H. Role of interstitial cells and gap junctions in the transmission of spontaneous Ca2+ signals in detrusor smooth muscles of the guinea-pig urinary bladder. J Physiol 2004; 559: 567-81
66. Thind P, Lose G, Colstrup H, Andersson KE. The influence of beta-adrenoceptor and muscarinic receptor agonists and antagonists on the static urethral closure function in healthy females. Scand J Urol Nephrol 1993; 27: 31-8
67. Yamaguchi O. Beta3-adrenoceptors in human detrusor muscle. Urology 2002; 59 (Suppl. 5): 25-9
68. Yamanishi T, Chapple CR, Yasuda K, Yoshida K, Chess-Williams R. Identification of beta-adrenoceptor subtypes in lower urinary tract of the female pig. J Urol 2002; 168: 2706-10
69. Badawi JK, Uecelehan H, Hatzinger M, Michel MS, Haferkamp A, Bross S. Relaxant effects of beta-adrenergic agonists on porcine and human detrusor muscle. Acta Physiol Scand 2005; 185: 151-9
70. Lagou M, Gillespie JI, Andersson KE, Kirkwood T, Drake MJ. Bladder volume alters cholinergic responses of the isolated whole mouse bladder. J Urol 2006; 175: 771-6
71. Burnstock G. Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. J Anat 1999; 194: 335-42
72. Ferguson D, Kennedy I, Burton T. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes - a possible sensory mechanism? J Physiol 1997; 505: 503-11
73. Kumar V, Chapple CR, Chess-Williams R. Enhanced urothelial ATP release in bladders of patients with neurogenic detrusor overactivity. J Urol 2006: Submitted
74. Kumar V, Chapple CR, Rosario DJ, Chess-Williams R. Purinergic activity in sensory disorders of the bladder. Eur Urol Suppl 2004; 3: 76, Abstract 295
75. Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol 2000; 129: 416-9
76. Templeman L, Chapple. CR, Chess-Williams R. Urothelium derived inhibitory factor and cross-talk among receptors of the bladder of the pig. J Urol 2002; 167: 742-5
77. Chaiyaprasithi B, Mang CF, Kilbinger H, Hohenfellner M. Inhibition of human detrusor contraction by a urothelium derived factor. J Urol 2003; 170: 1897-900
78. Chess-Williams R, Manandar A, Scott RL, Chapple CR. Which muscarinic receptor subtype predominates in the urothelium. Fundamental Clin Pharmacol 2004; 18 (Suppl. 1): 32, P03-15
79. Fovaeus M, Fujiwara M, Hogestatt ED, Persson K, Andersson KE. A non-nitrergic smooth muscle relaxant factor released from rat urinary bladder by muscarinic receptor stimulation. J Urol 1999; 161: 649-53
80. Inci K, Ismailoglu UB, Sahin A, Sungur A, Sahin-Erdemli I. The effect of inflammation on rat urinary bladder-dependent relaxation in coaxial bioassay system. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 547-52
81. Szallasi A. The vanilloid (capsaicin) receptor: receptor types and species differences. Gen Pharmacol 1994; 25: 223-43
82. Wein AJ. Neuromuscular dysfunction of the lower urinary tract and its management, In Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ eds, Campbell's Urology, 8th edn, Vol. II, Chapt. 26. Philadelphia: WB Saunders Co, 2002
83. Maggi CA. The dual efferent and sensory function of the capsaicin-sensitive primary sensory neurones in the urinary bladder and urethra. In Maggi CA ed., The Autonomic Nervous System: Nervous Control of the Urogenital System, Vol. 3, Chapt. 11. Switzerland: Harwood Academic Publishers, 1993: 383-422
84. Ishizuka O, Mattiasson A, Andersson KE. Urodynamic effects of intravesical resiniferatoxin and capsaicin in conscious rats with and without outflow obstruction. J Urol 1995; 154: 611-6
85. Szallasi A, Blumberg PM. Vanilloid receptors: new insights enhance potential as a therapeutic target. Pain 1996; 68: 195-208
86. Kuo HC. Inhibitory effect of capsaicin on detrusor contractility: further study in the presence of ganglionic blocker and neurokinin receptor antagonist in the rat urinary bladder. Urol Int 1997; 59: 95-101
87. Montecucco C, Molgo J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 2005; 5: 274-9
88. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004; 171: 2128-37
89. Aoki KR. Pharmacology and immunology of botulinum toxin type A. Clin Dermatol 2003; 21: 476-80
90. Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004; 45: 987-93
91. Apostolidis A, Popat R, Yiangou Y et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977-83
92. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996; 55: 1023-9
93. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342: 665
94. Lee SJ, Nakamura Y, de Groat WC. Effect of (+/-)-epibatidine, a nicotinic agonist, on the central pathways controlling voiding function in the rat. Am J Physiol Regul Integr Comp Physiol 2003; 285: R84-90
95. Yokoyama O, Yoshiyama M, Nimiki M, de Groat WC. Glutamatergic and dopaminergic contributions to rat bladder hyperactivity after cerebral artery occlusion. Am J Physiol 1999; 276: R935-42
96. B receptor agonists on cystometry in conscious mice. J Urol 2002; 167 (Suppl.): 39-40, Abstract 157
97. Carbone A, Tubaro A, Morello P, Parascani R, Catalani C, Palleschi G. The effect of gabapentin on neurogenic detrusor overactivity, a pilot study. Eur Urol Suppl 2003; 2: 141, Abstract 555